VUB-VIB spin-off and emerging drug discovery company Confo Therapeutics has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the company’s proprietary pre-clinical programs, targeting a neurological orphan indication.
Cedric Ververken, CEO of Confo Therapeutics: “This new grant will allow us to progress novel GPCR-modulating compounds against a neurological orphan indication further into pre-clinical development. We are excited about the potential of our approach to treating this particular indication and are grateful to VLAIO for its support of this project.”
Read more.
